A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety

Summary

This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of whole plant, hemp-derived CBD twice daily for six weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. Quality of life, sleep, general health, and cognitive function will also be assessed.

Timeline

Start

2021-02-01

Primary completion

2023-08-24

Completion

2023-08-24

Outcome

Outcome not reported

Stopped: “Terminated by sponsor”

Drugs

Indications